PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
4 hedge funds and large institutions have $9.43M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
5% more capital invested
Capital invested by funds: $8.95M → $9.43M (+$479K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.26M |
| 2 |
Morgan Stanley
New York
|
+$30.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$81K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $6.38M | +$4.26M | +68,966 | +110% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $3.02M | – | – | – |
|
|
3
Morgan Stanley
New York
| $24K | +$30.3K | +490 | New |
|
|
ACM
4
ACT Capital Management
Wayne,
Pennsylvania
| $10K | +$12.4K | +200 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$81K | -1,134 | Closed |
|
PHXM Hedge Fund Activity: Q2 2021 in Review
4 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q2 2021, worth a combined $9.43M — up 5.4% from $8.95M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PHXM positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.26M. The largest seller was Citadel Advisors, exiting entirely with an estimated $81K sold.
- 4 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q2 2021, up from 3 in Q1 2021.
- Funds reported $9.43M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q2 2021, up 5.4% quarter-over-quarter.
- 2 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q2 2021 and 1 closed out, a net change of +1 holder.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q2 2021 was BVF Inc, an estimated $4.26M added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q2 2021 was Citadel Advisors, an estimated $81K sold.
Based on aggregated 13F filings for Q2 2021.